BMO maintains Novo Nordisk stock target post FDA nod
BMO Capital Markets affirmed their positive stance on Novo Nordisk (NYSE:NVO) shares, maintaining an Outperform rating and a $105.00 price target. This confirmation followed the U.S. Food and Drug ...
As RFK Jr.’s hearings begin, so will scrutiny on his familiarity with key health programs
The job Robert F. Kennedy Jr. is seeking is defined by the task of overseeing Medicare and Medicaid, which he's shown little ...
Texas Public Radio39m
Caroline Kennedy calls her cousin, RFK, Jr., a 'predator' ahead of his confirmation hearings
In a letter, Kennedy said RFK Jr. was 'unqualified' to be the new U.S. Department of Health and Human Services secretary just ...
US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...